SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing intense market volatility and polarizing sentiment as traders debate whether it is a legitimate high-growth asset or a manipulated pump-and-dump scheme. The community is actively tracking major upcoming music events and supply concentration concerns while comparing the token's explosive price action to similar high-beta opportunities.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is trending as investors show strong interest in its potential for a mid-term rally, with many in the community highlighting its undervalued status relative to its TVL and its role as a benchmark DeFi lending protocol. The discourse is fueled by bullish technical setups, speculation around institutional integration, and debates comparing its tokenomics and governance to other major lending platforms.

TokenOS is the world’s most advanced AI-powered Web3 development platform, designed to turn natural language prompts into fully functional, production-ready blockchain applications. From simple tokens and memecoins to complex DeFi protocols, TokenOS automates the creation, deployment, and auditing of smart contracts and dApps with enterprise-grade reliability. By combining advanced language models with blockchain infrastructure, TokenOS removes the barriers of technical expertise, making Web3 development accessible to everyone. With instant deployment, built-in security best practices, and cross-chain support on the roadmap, TokenOS empowers entrepreneurs, developers, and creators to launch tokenized businesses and decentralized applications in seconds.

TokenOS AI

TokenOS AI is gaining momentum among retail traders who view the low-cap project as a high-potential, long-term opportunity within the rapidly expanding AI crypto sector. Community members are actively comparing the token's growth prospects against established AI infrastructure assets, emphasizing its status as an emerging, under-the-radar play.

Murphy Oil Corp. is a holding company, which engages in the exploration and production of oil and natural gas. It operates through the Exploration and Production, and Corporate and Other segments. The Exploration and Production segment includes the United States, Canada, and all other countries. The Corporate and Other segment focuses on interest income, other gains and losses, interest expense, and unallocated overhead. The company was founded by Charles H. Murphy Jr. in 1950 and is headquartered in Houston, TX.

Murphy Oil Corp.

Murphy Oil is drawing significant investor interest as analysts highlight its strong production growth and strategic focus on key offshore assets in the Gulf of Mexico and Vietnam. The community is actively debating the company's long-term potential, with a mix of optimism surrounding its recent earnings performance and ongoing discussions about debt management and global economic pressures in the energy sector.

Qnity Electronics, Inc. engages in the manufacturing of electronic materials to the semiconductor and electronics industries. Its brands include Acuplane, Circuposit, Duroptix, EPIC, Ikonic, Kalrez, Kapton, Laird, Microfill, Pyralux, Riston, Solderon Tin, and Silveron Silver. Its products include printed circuit board materials, display materials, electrical insulation materials, electronic components, semiconductor fabrication and packaging materials, thermal management materials, general metal finishing, plating on plastics, silver nanowire technologies, and other related products. It operates through the Semiconductor Technologies and Interconnect Solutions segments. The Semiconductor Technologies segment provides a portfolio of innovative materials and solutions utilized across multiple stages of the semiconductor manufacturing process. The Interconnect Solutions segment offers solutions for advanced electronics hardware, including complex printed circuit boards and advanced semiconductor packaging. The company was founded on December 6, 2024 and is headquartered in Wilmington, DE.

Qnity Electronics Inc

Qnity Electronics is attracting significant attention as traders identify it as a key beneficiary of the semiconductor and data center supply chain, compounded by its inclusion in Apple's American Manufacturing Program. The community is heavily focused on its post-spinoff structure and technical breakout potential, with many discussing its long-term growth prospects as a 'hidden gem' and potential multi-year compounder.

Tidal Trust II - Defiance Daily Target 2X Long IREN ETF

Defiance Daily Target 2X Long IREN ETF

The Defiance Daily Target 2X Long IREN ETF ($IRE) is seeing heavy social media volume as traders speculate on the aggressive price action of its underlying asset, with community members actively discussing the potential for a rebound following recent volatility. While some participants are aggressively "loading the boat" on dips and highlighting the strength of the data center sector, others are exercising caution with stop-losses and hedging strategies amid broader market uncertainty.

Terrestrial Energy, Inc. is an advanced nuclear technology company focused on next-generation nuclear energy systems. The company is developing the Integral Molten Salt Reactor (IMSR), an innovative type of Generation IV molten salt reactor designed to produce reliable, low-carbon heat and electricity at competitive costs. The company is headquartered in Charlotte, NC.

Terrestrial Energy Inc.

Terrestrial Energy is trending as investors focus on its progress within the Department of Energy's pilot program and potential advancements in molten salt reactor technology. While some community members highlight upcoming regulatory milestones and strong cash reserves, others express skepticism regarding the company's long-term commercial timeline and the absence of concrete revenue, leading to active debate over its valuation.

Daddy Darth Sidious

SIDIOUS is gaining traction alongside DARTH as part of a competitive, themed 'daddy wars' community narrative. Participants are actively debating potential market rotations and speculative entry points while emphasizing long-term holding strategies for these nano-cap assets.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending due to significant speculation surrounding the potential appointment of a former company executive as the new director of the FDA's Center for Biologics Evaluation and Research (CBER). The community is actively discussing this news as a major catalyst for the accelerated approval of Deramiocel, with many viewing the company's strong clinical data and exosome technology as a golden opportunity.

Daddy Darth Vader

The community is actively engaged in a rivalry known as the Daddy Wars, pitting DARTH against other related meme coins in a battle for market dominance. Traders are debating the project's long-term potential and the transparency of its leadership while weighing the risks of low-market-cap assets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wealth Effects LLC Reduces Stock Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Wealth Effects LLC lessened its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 14.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 143,300 shares of t...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Cross Above 200-Day Moving Average   - Here's Why

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Crosses Above Two Hundred Day Moving Average - Should You Sell...

Aberdeen Group plc Sells 234,498 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Aberdeen Group plc cut its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 45.0% during the 4th quarter, according to its most recent disclosure with the...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven analysts that are presently covering the firm...

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiologys 75th Annual Scientific Session and Expo

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced long-term efficacy and safety data from a two-year long open-label extension (OLE) study of investigational plozasiran supporting its...

<ul class="summary-bullets"><li>Wave said earlier on Thursday that individuals administered a single 240 mg dose of WVE-007 showed a body weight reduction of 0.9% in the early stage portion of its trial.</li><li>Jones Research attributed WVE’s selloff on Thursday to the low total weight loss at six months, 0.9% versus hopes for 2% or 3%.</li><li>Unlike traditional GLP-1 drugs that often lead to muscle loss, Arrowhead’s obesity candidates, ARO-INHBE and ARO-ALK7, aim to reduce body fat, while specifically preserving lean muscle mass.</li></ul> Shares of Arrowhead Pharmaceuticals Inc. (ARWR) fell nearly 2% on Thursday before paring back losses after Wave Life Sciences (WVE) announced mixed data from the early stage portion of its trial evaluating its investigational drug WVE-007 in individuals with obesity.Leerink analyst Mani Foroohar said that they are not surprised to see ARWR stock down as material obesity value is baked in at Arrowhead’s $8.5 billion market cap. The firm has a ‘Market Perform’ rating on Arrowhead shares.Wave said earlier on Thursday that individuals administered a single 240 mg dose of WVE-007 showed a body weight reduction of 0.9% in the early stage portion of the trial, with clinically meaningful reductions in visceral fat and waist circumference, after six months. The investigational drug was well tolerated to date up to 600 mg with no treatment discontinuations, the company said.<a href="https://stocktwits.com/symbol/WVE">WVE shares</a> traded 50% lower at the time of writing. &nbsp;<h2 class="st-heading-2">Why The WVE Selloff?</h2>Jones Research attributed WVE’s selloff to the low total weight loss at six months, 0.9% versus hopes for 2% or 3%. The firm believes that while WVE-007 may not be competitive to GLP-1 category weight loss drugs in the general population, there is still a chance for utility in the elderly or patients with metabolic disease.Jones Research has a ‘Buy’ rating on Wave Life with a $35 price target.Leerink analyst Joseph Schwartz, meanwhile, said that the firm likes the continued improvement in visceral fat reduction at 240 mg after six months, as well as the larger reduction on waist circumference and measurable body weight reduction. The stock's reaction premarket seems to remove all value for WVE-007, which is "very overdone," the firm said. Leerink has an ‘Outperform’ rating on WVE shares.<h2 class="st-heading-2">Arrowhead’s Obesity Pipeline</h2>Unlike traditional GLP-1 drugs that often lead to muscle loss, Arrowhead’s obesity candidates, ARO-INHBE and ARO-ALK7, aim to reduce body fat while specifically preserving lean muscle mass.While comparisons between Wave and Arrowhead data are impaired by small numbers of patients, differences in baseline, and other factors, the greater than 50% fall in Wave's stock price "highlights the degree of optimism baked into INHBE expectations" and brings questions related to Arrowhead "back to center stage," Foroohar told investors, as per TheFly.BofA, meanwhile, lowered the firm's price target on Arrowhead to $81 from $84 and kept a ‘Buy’ rating on the shares. The analyst said that Wave’s update appears largely priced in.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ARWR stock improved from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/ARWR">ARWR stock</a> has more than quadrupled over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/htz-stock-soars-tsa-delays-airports-spike-in-car-rental-searches/cZ3sTFCRIke">HTZ Stock Soars After TSA Delays At Airports Reportedly Result In Spike In Car Rental Searches</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen.

ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It?

Leerink analyst Mani Foroohar said that they are not surprised to see Arrowhead Pharmaceuticals’ stock down as material obesity value is baked in at the company’s $8.5 billion market cap.

Equity

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down   - What's Next?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Down - Here's What Happened...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives "Buy" Rating from HC Wainwright

HC Wainwright reiterated a "buy" rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 8.6% - Here's What Happened

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Up 8.6% - Time to Buy...

Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Nordea Investment Management AB

Nordea Investment Management AB lowered its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 12.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 324,251 shares of the biotechnology comp...

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

ARWR
Arrowhead Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ARWR News

ARWRArrowhead Pharmaceuticals Inc.